Faculty Sponsor

Jana Stedman




Physician Assistant Program

Presentation Type

Poster Presentation

Symposium Date

Summer 7-26-2023


Objective: To further analyze if GLP-1 agonists are more effective in weight loss in obese patients with type 2 diabetes or without type 2 diabetes over the course of 1 year. Obesity has an increasing prevalence in those with and without type 2 diabetes so the need to find a treatment that can potentially treat both diseases can lead to less comorbidities and better outcomes. Methods: Online databases were used to find academic sources that compared the use of GLP-1 agonists for weight loss in those with and without type 2 diabetes. Ten sources, including meta analyses, retrospective cohorts, narrative reviews, and systematic reviews published within the last 5 years were included in this research paper. Results: GLP-1 agonists, such as Liraglutide and Semaglutide, were found to be statistically more effective for weight loss in adult patients who do not have type 2 diabetes over those with type 2 diabetes. Patients with type 2 diabetes were still found to have more weight loss with a GLP-1 agonist than with a placebo, but those without type 2 diabetes had significantly higher weight loss.

Biographical Information about Author(s)

Alyssa Comerford has an anticipated graduation date of July 2023 from the Valparaiso University Physician Assistant program. She plans on working in either family medicine or dermatology following graduation. She is a student member of the American Academy of Physician Associates (AAPA), as well as the Valparaiso University Physician Assistant Student Society (VUPASS). She will be presenting on “GLP-1 agonists and their effects on diabetes and weight loss” which she became interested in after seeing how many patients were requesting Ozempic regardless of diabetes diagnosis.